Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 due to lack of tolerability and efficacy.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Nothing like Hippo for cooling investor enthusiasm
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.
